Market Cap 14.06B P/E 16.98 EPS this Y 3,200.00% Ern Qtrly Grth 1,326.00%
Income 852.03M Forward P/E 1,548.70 EPS next Y -98.80% 50D Avg Chg -8.00%
Sales 1.86B PEG 0.66 EPS past 5Y 37.13% 200D Avg Chg -6.00%
Dividend N/A Price/Book 3.47 EPS next 5Y 32.16% 52W High Chg -41.00%
Recommedations 2.10 Quick Ratio 2.24 Shares Outst. 181.53M 52W Low Chg 13.00%
Insider Own 0.61% ROA -0.80% Shares Float 180.23M Beta 0.60
Inst Own 100.25% ROE 23.91% Short Shares 0 Price 77.44
Gross Margin 38.89% Profit Margin 45.74% Avg. Volume 1,420,414 Target Price 110.70
Oper. Margin -3.68% Earnings Apr 27 Volume 2,338,790 Change -5.29%
BioMarin Pharmaceutical Inc. News
02/26/21 BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
02/26/21 Biomarin Pharmaceutical Inc (BMRN) Q4 2020 Earnings Call Transcript
02/26/21 BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull
02/25/21 BioMarin Pharmaceutical, Inc. to Host Earnings Call
02/24/21 Biomarin Pharmaceutical's Earnings Outlook
02/24/21 BioMarin to Participate in Four Upcoming Virtual Investor Conferences
02/18/21 BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors
02/11/21 ALXN vs. BMRN: Which Stock Is the Better Value Option?
02/06/21 Should BioMarin Pharmaceutical (NASDAQ:BMRN) Be Disappointed With Their 22% Profit?
09:00 AM BioMarin Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index
01/26/21 ALXN vs. BMRN: Which Stock Should Value Investors Buy Now?
01/26/21 BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET
01/22/21 Is Now A Good Time To Buy BioMarin Stock?
01/12/21 Stock Market News for Jan 12, 2021
01/11/21 BioMarin's stock tumbles 6% after sharing data about experimental hemophilia A drug
01/11/21 BioMarin’s One-Year Data on Its Hemophilia Gene-Therapy Looked Good. Can It Win FDA Approval?
01/11/21 BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy
01/11/21 Gene-Therapy Firm Bluebird Bio Is Spinning Off Its Cancer Programs
01/10/21 BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.

BMRN Chatroom

User Image Insider_Analysis Posted - 1 day ago

$BMRN In the recent reporting quarter: 182 institutions increased their position, while 152 decreased https://insider-analysis.com/search_whales.php?ticker=TABLE_BMRN

User Image quantcha Posted - 1 day ago

StockTwits Trending Alert: Trading recent interest in BIOMARIN PHARMACEUTICAL $BMRN https://wp.me/p5bLGB-clvZ

User Image CZARBETS Posted - 1 day ago

$BMRN 3 Big Trades Today - $57.30M 740,010 shares at $77.43 average

User Image fla Posted - 1 day ago

$BMRN [15s. delayed]: Issued Press Release on February 26, 22:50:00: BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL https://s.flashalert.me/HBdHtS

User Image ChartMill Posted - 1 day ago

$BMRN: BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates ... https://www.chartmill.com/stock/quote/BMRN/news?utm_source=stocktwits&utm_medium=pressRelease&utm_content=BMRN&utm_campaign=social_tracking

User Image Stock_Titan Posted - 1 day ago

$BMRN BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN https://www.stocktitan.net/news/BMRN/biomarin-investigation-initiated-by-former-louisiana-attorney-woakjor50qjt.html

User Image marketchameleonwins Posted - 1 day ago

$BMRN earnings move -5.3% vs an expected ±11.6% move https://tinyurl.com/y9jyz95z

User Image sleekoptions_twits Posted - 1 day ago

$BMRN volume up by +156.23 % | 3,291,564 vs 1,284,627 https://www.sleekoptions.com/sleekscan.aspx?did=BMRN

User Image Last10K Posted - 1 day ago

Last10K highlighted 50 positive and negative remarks in $BMRN's 10-K filed today. See them in the Annual Report: https://last10k.com/sec-filings/BMRN/0001048477-21-000008.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=sentiment&utm_term=bmrn

User Image Last10K Posted - 1 day ago

$BMRN just filed a 10-K Annual Report with 101 sections and 6 exhibits. Access them all or just read their earnings: https://last10k.com/sec-filings/bmrn/0001048477-21-000008.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=bmrn

User Image CZARBETS Posted - 1 day ago

$BMRN Big Trade - $24,135,318 311,705 shares at $77.43

User Image CZARBETS Posted - 1 day ago

$BMRN Big Trade - $9,028,338 116,600 shares at $77.43

User Image risenhoover Posted - 1 day ago

$BMRN / BioMarin Pharmaceutical files form 10-K https://fintel.io/sf/us/bmrn?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

User Image cctranscripts Posted - 1 day ago

BioMarin Pharmaceutical Inc. just filed its Annual report [Section 13 and 15(d), not http://www.conferencecalltranscripts.org/include?location=http://www.sec.gov/Archives/edgar/data/1048477/000104847721000008/0001048477-21-000008-index.htm $BMRN

User Image fla Posted - 1 day ago

$BMRN [15s. delayed] filed form 10-K on February 26, 15:16:19 https://s.flashalert.me/s5wUgK

User Image Quantisnow Posted - 1 day ago

$BMRN 📜 SEC Form 10-K filed https://quantisnow.com/insight/446711?s=s #majorpharmaceuticals #healthcare

User Image Newsfilter Posted - 1 day ago

$BMRN Form 10-K (annual report [section 13 and 15(d), not s-k item 405]) filed with the SEC https://newsfilter.io/a/e7535b6a630bba74619ea2abf4976d50

User Image PippoBaudo Posted - 1 day ago

$BMRN

User Image scienceleads Posted - 1 day ago

$BMRN doubtful that this gene therapy and rare disease company sits here for 6 more months. Just saying, long term view

User Image Dtmzb Posted - 2 days ago

$BMRN it is moving sideways.tgere us no much volume to push price up.

User Image Sukoneet Posted - 2 days ago

$BMRN Jesus that’s quite a dip given quarterly should have been positive against the macro headwinds. The market and I agree on this one. Not enough catalysts for this this year. Will move sidewards for another six months, best case maybe increase a little as a safe haven.

User Image Dtmzb Posted - 2 days ago

$BMRN this is not a good news. It did not recover from look at year price crash of 135. I see it is closing today low of the week at 75.i am out. I was hoping it will go up after reporting yesterday.

User Image STCKPRO Posted - 2 days ago

$BMRN NEW ARTICLE : Why Biomarin Pharmaceutical's Stock is Down During Today's Session https://www.stck.pro/news/BMRN/11264495

User Image zghorner Posted - 2 days ago

$BMRN puts printing today this thing is headed for $60s eventually

User Image GoldenEye25 Posted - 2 days ago

$BMRN so bad. So bad.

User Image Top_Dog_Pro_Trader Posted - 2 days ago

$BMRN $IBB $XBI $XLV $BBH I thought the results beat. No one should have been surprised Kuvan sales we’re heading down. The reason guidance is lower is from delay in HemA app, which is not new . Give the stock has been beaten up, seems very cheap give the pipeline outlook.

User Image scienceleads Posted - 2 days ago

$BMRN revenues on the rise, generic drug comp built in, a new gene therapy for pku, and 2 late stage in Hemo A and small stature drug. Real talent driving this science. imho long term view constructive

User Image MrcDarkPoolTrading Posted - 2 days ago

$SRG $VST $MNST $BMRN $ONEM Pre ER with unusual option volume list. Couple of these had dark pool orders

User Image cctranscripts Posted - 2 days ago

Going through reasons presented as to $BMRN transcript http://www.conferencecalltranscripts.org/include?location=https://seekingalpha.com/article/4409317-biomarin-pharmaceuticals-bmrn-ceo-j-j-bienaime-on-q4-2020-results-earnings-call-transcript?utm_source=conferencecalltranscripts.org

User Image PippoBaudo Posted - 2 days ago

$BMRN

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own
BIENAIME JEAN JACQUES Chief Executi.. Chief Executive Officer Feb 22, 8:38 PM Option 26.49 7,000 185,430 302,552
BIENAIME JEAN JACQUES Chief Executi.. Chief Executive Officer Feb 22, 8:38 PM Sell 83.58 7,000 585,060 295,552
BIENAIME JEAN JACQUES Chief Executi.. Chief Executive Officer Feb 19, 9:22 PM Option 26.49 7,000 185,430 302,552
BIENAIME JEAN JACQUES Chief Executi.. Chief Executive Officer Feb 19, 9:22 PM Sell 85.08 7,000 595,560 295,552
BIENAIME JEAN JACQUES Chief Executi.. Chief Executive Officer Feb 18, 9:45 PM Option 26.49 8,000 211,920 303,552
BIENAIME JEAN JACQUES Chief Executi.. Chief Executive Officer Feb 18, 9:45 PM Sell 84.54 8,000 676,320 295,552
LAWLIS V BRYAN Director Director Feb 18, 6:43 PM Option 26.49 7,500 198,675 26,350
LAWLIS V BRYAN Director Director Feb 18, 6:43 PM Sell 87.41 7,500 655,575 18,850
BIENAIME JEAN JACQUES Chief Executi.. Chief Executive Officer Feb 1, 7:00 PM Option 26.49 16,667 441,509 303,886
BIENAIME JEAN JACQUES Chief Executi.. Chief Executive Officer Feb 1, 7:00 PM Sell 82.79 16,667 1,379,861 295,552
BIENAIME JEAN JACQUES Chief Executi.. Chief Executive Officer Jan 28, 7:35 PM Option 26.49 8,333 220,741 303,885
BIENAIME JEAN JACQUES Chief Executi.. Chief Executive Officer Jan 28, 7:35 PM Sell 85.49 8,333 712,388 295,552
BIENAIME JEAN JACQUES Chief Executi.. Chief Executive Officer Dec 30, 8:02 PM Sell 88.48 3,000 265,440 295,552